Gilead shows its belief in its partner’s cancer treatment with a $7.8 billion buyout
Short excerpt below. Click through to read at the original source.
Arcellx’s stock is heading toward a record after the $7.8 billion deal to be acquired by Gilead.
Short excerpt below. Click through to read at the original source.
Arcellx’s stock is heading toward a record after the $7.8 billion deal to be acquired by Gilead.